Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | NT5E | P21589 | 2/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | AHCY | P23526 | 4/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21132768 | 1.00 | LMNA (0.65) | LMNANT5EHIF1AAHCYADORA2A | |
| SCHEMBL3036906 | 1.00 | LMNA (0.65) | LMNANT5EHIF1AAHCYADORA2A | |
| SCHEMBL29056321 | 0.90 | NT5E (0.58) | LMNANT5EHIF1AAHCYADORA2A | |
| SCHEMBL8923952 | 0.89 | NT5E (0.62) | LMNANT5EHIF1AAHCYADORA2A | |
| SCHEMBL26291351 | 0.89 | NT5E (0.62) | LMNANT5EHIF1AAHCYADORA2A | |
| SCHEMBL8923951 | 0.89 | NT5E (0.62) | LMNANT5EHIF1AAHCYADORA2A | |
| SCHEMBL21562190 | 0.88 | AHCY (0.58) | LMNANT5EHIF1AAHCYADORA2A | |
| SCHEMBL3259052 | 0.88 | AHCY (0.58) | LMNANT5EHIF1AAHCYADORA2A | |
| SCHEMBL3952851 | 0.88 | AHCY (0.58) | LMNANT5EHIF1AAHCYADORA2A | |
| SCHEMBL29124737 | 0.88 | NT5E (0.56) | LMNANT5EHIF1AAHCYADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352387-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc (GB) | 2022-06-07 | — | — | US | claimed |
| EP-1898956-A4 | ANTI-TUMORAL COMPOSITIONS AND METHODS | UAB RESEARCH FOUNDATION (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1898956-A2 | ANTI-TUMORAL COMPOSITIONS AND METHODS | UAB Research Foundation (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2006124847-A2 | ANTI-TUMORAL COMPOSITIONS AND METHODS | UAB RESEARCH FOUNDATION (US) | 2006-11-23 | — | — | WO | claimed |
| EP-1444335-A4 | MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE PROTEINS AND CELLULAR DELIVERY THEREOF | UAB RESEARCH FOUNDATION (US) | 2006-03-08 | — | — | EP | claimed |
| US-20050214901-A1 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | CORNELL CENTER FOR TECHNOLOGY, ENTERPRISE & COIMMERCIALIZATION | 2005-09-29 | — | — | US | claimed |
| EP-1444335-A2 | MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE PROTEINS AND CELLULAR DELIVERY THEREOF | UAB Research Foundation (US) | 2004-08-11 | — | — | EP | claimed |
| US-20030228576-A1 | Nucleotide sequence coding for a cleaving enzyme; can use in conjuction with substrate to produce toxins which impair abnormal cell growth; antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-11 | — | — | US | claimed |
| WO-2003035012-A2 | MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE PROTEINS AND CELLULAR DELIVERY THEREOF | UAB RESEARCH FOUNDATION (US) | 2003-05-01 | — | — | WO | claimed |
| US-6177469-B1 | ANTIUTOR AGENTS; AUTOIMMUNE DISEASES | HEIDELBERG PHARMA HOLDING GMBH (DE) | 2001-01-23 | — | — | US | claimed |
| US-20250163096-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2025-05-22 | — | — | US | disclosed |
| US-12054510-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc (GB) | 2024-08-06 | — | — | US | disclosed |
| US-20220306675-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2022-09-29 | — | — | US | disclosed |
| US-11352387-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc (GB) | 2022-06-07 | — | — | US | disclosed |
| CN-111909231-A | 2 ' and/or 5 ' -amino acid ester phosphoramidate 3 ' -deoxyadenosine derivatives as anticancer compounds | 努卡那有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-6177469-B1 | ANTIUTOR AGENTS; AUTOIMMUNE DISEASES | HEIDELBERG PHARMA HOLDING GMBH (DE) | 2001-01-23 | — | — | US | disclosed |
| EP-0877605-A2 | SOLID INSTANT-RELEASE FORMS OF ADMINISTRATION AND PROCESS FOR PRODUCING THE SAME | Roche Diagnostics GmbH (DE) | 1998-11-18 | — | — | EP | disclosed |
| EP-0854708-A1 | LIPID ALCOHOLS AS NEW IMMUNOSUPPRESSIVE AND ANTIVIRAL DRUGS | Roche Diagnostics GmbH (DE) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997026867-A2 | SOLID INSTANT-RELEASE FORMS OF ADMINISTRATION AND PROCESS FOR PRODUCING THE SAME | BOEHRINGER MANNHEIM GMBH (DE) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997014410-A1 | LIPID ALCOHOLS AS NEW IMMUNOSUPPRESSIVE AND ANTIVIRAL DRUGS | BOEHRINGER MANNHEIM GMBH (DE) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306675-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, ADORA2A | LMNA 1393/4885NT5E 30/4885HIF1A 1811/4885 |
| US-12054510-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | MTAP, ADA, ADORA2A | LMNA 1328/4885NT5E 25/4885HIF1A 1749/4885 |
| US-11352387-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | MTAP, RNMT, ADA | LMNA 1196/4885NT5E 33/4885HIF1A 2252/4885 |
| US-20250163096-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, ADORA2A | LMNA 1393/4885NT5E 30/4885HIF1A 1811/4885 |
| US-20050214901-A1 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | PNP, UPP1, TYMP | LMNA 213/4885NT5E 44/4885HIF1A 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.